After reading letter, I like the study of patients with recurrent glioblastoma. These patients will receive leronlimab in advance of their pending surgery and then start an ICI after surgery.

Seems much easier to to get patients who are going to have procedure anyhow to get Leronlimab to stop metastasis than those in a trial where Leronlimab is the last resort cure.